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NASAL DOSAGE FORMS OF PROPRANOL 
'Thisis a division of application Ser. _No. 63,176, ?led 
Aug. 3, 1979, now vU.S. Pat. No. 4,284,648. ‘ ' 
BACKGROUND OF THE INVENTION 
‘ 1. Field of the Invention ‘ 
' The present invention relates to a novel method of 
administering propranolol, a B-adrenergic-blocking 
agent, and to novel dosage forms containing proprano 
lol adapted for nasal administration. 
'2. Description of ‘ the Prior Art 
Propranolol, a B-adrenergic-blocking agent, is widely 
used therapeutically, chie?y in the management of hy 
pertension and in the treatment of angina pectoris, ar-' 
rhythmias and other cardiac conditions, and migraine. 
The drug is, however, inefficiently and variably ab 
sorbed from oral dosage forms. Thus, Shand et al., Clin. 
Pharmacol. T herap. 11, 112-120 (1970), report a study in 
humans has shown that following Oral administration of 
propranolol, peak plasma levels in ?ve subjects given 80 
mg oral doses varied seven fold, while levels for 10 mg 
intravenous doses in the same subjects varied only two 
fold. Furthermore, the bioavailability of propranolol in 
some subjects as calculated from the ratio of the area 
under the curve of anI8O mg oral dose and 10 mg I.V. 
dose was found to be as low as 16%. The variations in 
the blood levels as well as the low bioavailability for 
oral doses has been attributed by various researchers to 
the extensive metabolism of the drug in the gastrointes 
tinal tract during the absorption process and/or to the 
effect of the ?rst pass through the liver [Dollery et al., 
Ann, N. I". Acad. Sci. 179, 109 (1971); ' Suzuki et al., 
Chem. Pharm. Bull. 20, 2731 (1972); and Garceau et al., 
JQPharm. Sci. 67, 1360 (1978)]. ' ‘ 
SUMMARY OF THE INVENTION 
In view of the foregoing, it is apparent that a serious 
need exists for the improved delivery of propranolol. 
Thus, 'it is an object of the present invention to provide 
novel dosage forms and a novel method of administer 
ing propranolol which will provide enhanced bioavaila 
bility and minimized variations in blood levels as com 
pared to oral dosage forms, while at the same time pro 
viding relative ease of administration when compared 
to the intravenous route. 
The foregoing object,‘ resulting in bioavailability of 
propranolol comparable to that achieved by‘intrave~ 
nous administration but without the disadvantages in 
herent in that route of administration, is achieved by 
nasal administration of propranolol. According to the 
invention, the propranolol is conveniently administered 
via a novel nasal dosage form, i.e., a'solution, ‘suspen 
sion, ointment or gel adapted for nasal-administration. 
BRIEF DESCRIPTION OF THE'DRAWINGS 
FIG. i is a semi-logarithmic plot of average blood 
levels of propranolol in rats obtained when the drug 
was administered via nasal, oral and intravenous routes; 
FIG. 2 is a semi-logarithmic plot of mean plasma 
levels of propranolol in dogs after administration of 20 
mg doses via nasal, intravenous and oral administration; 
and . . . 
FIG. 3 isia semi-logarithmic plot of mean bloodlevels 
of propranolol inrats after nasal admins‘tration of 1 mg , 
doses, via a nasal solution and via a sustained release 
nasal gel. 
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DETAILED DESCRIPTION THE 
‘ ‘ INVENTION 
The word “propranolol” as used herein is intended to 
5 encompass/any pharmaceutically acceptable form of 
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propranolol, i.e., the free base of a pharmaceutically 
‘acceptable salt or ester thereof. Propranolol, or l-(iso 
propylamino)-3-(l-naphthyloxy)-2-pr0panol, can be 
represented by the structural formula: 
Details of the chemical synthesis of the free base, as well 
as a description of pharmaceutically acceptable esters 
and salts which can be‘ derived therefrom, are set forth 
in Crowther et al. US Pat. No. 3,337,628, expressly 
incorporated by reference herein and ‘relied upon. 
According to the present invention, it has been sur 
prisingly found that propranolol can be administered 
nasally with results considerably superior to those ob 
tained with oral administration. The following study 
was undertaken to examine the bioavailability of pro 
pranolol from nasal solution in comparison with the 
bioavailability of the drug when administered orally 
and intravenously. . ' 
Sprague Dawley male rats, each weighing ‘about 270 
grams, were used in this study. For nasal administration, 
the rats were anesthetized using sodium pentobarbital 
(50 mg/kg) and the drug was administered to the nasal 
. cavity by means of a micropipet at dosage levels of l 
mg/rat and 2 mg/ rat in 0.1 ml of isotonic buffer solution 
(pH 7.2) according to the procedure described by Hirai 
et al., the 98th Annual Meeting of Pharmaceutical Soci 
ety of Japan, Okayama,April 1978. For intravenous 
administration, the rats were anesthetized and a 1 mg 
dose of the drug in 0.2 ml isotonic buffer solution (pl-I 
7.2) was injected into each rat through the femoral vein. 
After intravenous and nasal administration, blood from 
the femoral aorta was sampled periodically. For oral 
administration, the rats .were not anesthetized and 1 
mg/ rat doses of the drug in 1 ml isotonic buffer solution 
(pH 7.2) were administered by means of a stomach tube. 
After oral administration, blood from the tail vein was 
sampled periodically. Blood levels of the drug were 
determined vspectrophotofluorometrically by_ a minor 
modification of the method of Suzuki et al., Chem. 
Pharm. Bull. 20, 2731 (1972). 
FIG. 1 shows the mean blood levels of propranolol 
for the study described above. As seen from FIG. .1, the 
blood level of the drug after nasal adminstration of a 1 
mg dose is identical to the blood level after intravenous 
administration of a 1 mg dose, whereas oral administra 
tion at the same dosage level results in considerably 
lower blood levels. The oral bioavailabilities calculated 
from the ratio of the area under the curve (oral 
/I.V.)>< 100 and (oral/nasal)>< within 4 hours after 
administration were found to be about‘ 15%. Table I 
shows the area under the curve (AUC) within 4 hours 
after intravenous, nasal and oral administration of pro 
pranolol (mg/rat) in rats. , , V I 
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TABLE I ' 
AREA UNDER CURVE (AUC) WITHIN 4 HOURS AFTER 
INTRAVENOUS, NASAL AND ORAL‘ ADMINISTRATION 
" ' OF PROPRANOLOL (1 mg) IN RATS‘ " ' 
. ‘ Percentage 
AUC04 . ' Absorbed Compared 
Route . (ng hr ml* 1) mRatio- to I.V. Route 
Intravenous 8072-: 32.9- . . _~ . ' >1 . ‘ 
Nasal 804.0 $156.4, 2 0.996 . -:99.6% 
Oral 144.5 : 22.8 0.179 17.9% 
‘mean t SE 
It can also be seen from FIG. 1 that the area under the 
blood level curve is directly proportional to the dose, 
when the drug is administered‘ nasally. Further, it can be 
seen that propranolol is very rapidly absorbed from the 
nasal mucosa; thus, the peak plasma level is attained 
within 5 minutes of the instillation of the nose drops. 
The advantages of nasal administration as-compared 
to oral administration has also been demonstrated in 
tests in dogs. Details of the test procedure-are set forth 
below. ., , . ‘ 
Three beagledogs weighing about 10 kg each were 
used for this crossover study. For nasal administration, 
the dogs were anesthetized _with the intravenous injec 
tion of 30 mg/kg of sodium pentobarbital, and 0.2 ml of 
saline solution containing propranolol hydrochloride 
(20 mg/ dog) was theb administered to the nasal cavity 
via a ‘micropipet. For intravenous administration, the 
dogs were anesthetizedv and a 20 mg/dog dose of the 
drug in 1.0‘ ml saline solution was injected through the 
forelag vein. For oral administration, the dogs were not 
anesthetized and a 20 trig/dog dose of the drug in 50 ml 
of water was ‘administered via a stomach tube. After 
nasal, intravenous and-‘oral administration, blood was 
sampled from the' foreleg ‘vien periodically. Plasma 
levels of propranolol ‘were determined spectrophoto 
fluorometrically by a minor‘modi?cation of the method 
of Shand et al., CIin. Pharmacql. Therap. 11, 112-120 
(1970). ‘ ‘ '7 ' " ‘ 
FIG. 2 shows the mean plasma levels of propranolol 
for the study described immediately above. As can be 
seen from FIG. 2, the plasma levels of the drug after 
intravenous and nasal administration are virtually iden 
tical, whereas oral'administration results in considera 
bly lower plasma levels."Table II below summarizes the 
results obtained for each individual dog for the three 
routes of administration. ' ' - 
' ‘TABLE II 
AREA UNDER PLASMA CURVE WITHIN 8 HOURS 
AFTER INTRAVENOUS, NASAL AND ORAL 
‘ADMINISTRATION OF PROPRANOLOL (20 mg) IN DOGS 
Intra- ‘ ' v " 
venous Nasal Oral . 
_ (ng hr ‘,(ng hr.’ .(ng hr AUCiNasal! AUC§P.O.! 
Dog ml" 1) 1 ml,“ 1) ml" 1) AUC(I.V.) AUC(I.V.) 
N106 1702.6 1648.0 151.8 , 0.967 0.089 
I096 1548.1 1538.9 I 93.8 I 0.994 0.059 
1.196 1534.9 ‘1556.3 117.9 ' 1.013 0.076 
Mean 1595.2 ‘ 1581.0 120.8 0.991 ‘ 0.074 
53.8 33.7 0.013 0.008 SE 17.0 
As can be seen’ from Table II supra; the bioavailabil 
ity of propranolol from the oral route is only 7.4% of 
that of the intravenous route,i'wherelas the bioavailabil 
ity from the nasal route is 99.1% that of the intravenous 
route. These results ‘and those from the'study, in rats 
detailed above indicate that propranolol is rapidly ab 
4 
sorbed from the nasalmucosa into systemic blood‘ with 
. out the first pass metabolism. ' 
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Propranolol can be conveniently administered na 
sally to warm-blooded animals by formulating it into a 
nasal dosage form comprising propranolol and a non 
toxic pharmaceutically acceptable nasal‘. carrier there 
for. As indicated earlier, propranolol can be employed 
in the form of the free base or in the form of a-pharma 
ceutically acceptablesaltlorester thereof, e. g., propran 
olol hydrochloride or. propranolol stearate. Suitable 
nontoxic pharmaceutically acceptable nasal carriers 
will be apparent to those skilled in the art of nasal phar 
maceutical formulations. For those not skilled in the art, 
reference is made to the text entitled “REMINGTONZS 
PHARMACEUTICAL SCIENCES”, 14th edition, 
1970. Obviously, the choice of suitable carriers will 
depend on the exact nature of the particular nasal dos‘ 
age form desired, e.g., whether propranololv is to'; be 
formulated into a nasal solution (for use as drops or as a 
spray), a nasal suspension, a nasal ointment or a nasal 
gel. Preferred nasal dosage forms are solutions and’gels, 
which contain' a major amount of water (preferably 
puri?ed water) in addition to theeactive ingredient. 
Minor amounts of other ingredients such as'pH adjust 
ers (e.g., a base such as NaOH)‘, buffering agents, preser-' 
vatives, wetting agents and jelling agents (e.g., methyl- 
cellulose) may also be present. ' ' 
Examples of the preparation of a typical nasal solu- ‘ 
tion and of a sustained release nasal gel containing pro 
pranolol are set forth below. However, it is to be underi 
stood that these examples are given by way ‘of illustra 
tion only and are not to be construed as limiting the 
invention either in spirit or in scope as many modi?ca 
tions both in materials and in methods will be apparent 
to those skilled in the art. ‘ 
‘EXAMPLE 1 ' 
' 2 Grams of propranolol hydrochloride were dis 
solved in 80 ml of distilled water and the pH of the 
resultant solution was adjusted to 7.4 with dilute sodium 
hydroxide solution. A quantity of water sufficient to 
bring the total volume to 100 ml was then added. The 
solution was sterilized by being passed through a 0.2 
micron Millipore ?lter. 
EXAMPLE 2 
80 Grams of water were heated to 80° C. and 3.0 
grams of Methocel were added, with stirring. The resul 
tant mixture was allowed to stand at room temperature 
for 3 hours. Then, 1.84 grams of propranolol stearate 
were suspended in 20 grams of water and the suspension 
was added to the gel and thoroughly mixed. . 
A sustained release gel prepared as described'abov 
was nasally administered to rats at the l mg/rat dosage 
level. FIG. 3 shows the mean blood levels of proprano 
lol obtained as compared to those obtained'for a- 1mg 
dose of nasal‘ solution. The plot clearly shows that pro 
longed release of propranolol can be achieved via‘nasal 
administratiom" 5' I i a ‘v' 
EXAMPLE 3 
A novel dosage form of an aqueous solution of pro; 
pranolol inv a pharmaceutical vehicle and suitable for use 
as nasal drops or‘ nasal spray was prepared.‘ The ?nal 
compositlo'nfadjusted to pH 7.4, had the following 
composition: F > ' 
4,394,390 
INGREDIENT AMOUNT “ 
propranolol hydrochloride 500 mg 
Tween 80 2 mg 
methyl cellulose 20 mg 
water 10 ml. 
Naturally, the therapeutic dosage range for nasal 
administration of propranolol according to the present 
invention will vary with the size of the patient and the 
condition for which the drug is administered. A typical 
dose of propranolol would be 10 to 100 mg adminis 
tered nasally three times daily. The quantity of nasal 
dosage form needed to deliver the desired dose will of 
course depend on the concentration of propranolol in 
the composition. The volume of solution or gel which 
would be needed to deliver the typical dose of active 
ingredient speci?ed above would be 0.1 to 0.5 ml of 
10% solution or gel‘. 
While the invention has been described in terms of 
various preferred embodiments, the skilled artisan will 
appreciate that various modi?cations, substitutions, 
omissions and additions may be made without departing 
from the spirit thereof. Accordingly, it is intended that 
the scope of the present invention be limited solely be 
the scope of the following claims. 
What is claimed is: 
ll. A pharmaceutically acceptable nasal composition, 
in dosage unit form, for nasal administration to obtain a 
systemic therapeutic ,B-adrenergic blocking response in 
a warm-blooded animal, consisting essentially of, per 
nasal dosage unit, (i) a systemically therapeutically ef 
fective unit B-adrenergic blocking amount of a com 
pound having the formula 
15 
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or a nontoxic pharmaceutically acceptable ester of salt ‘ 
thereof, and (ii) a nontoxic pharmaceutically acceptable 
nasal carrier therefor, said composition being formu 
lated as a nasal ointment or a nasal gel adapted for sus 
tained release to the nasal mucosa. 
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2. The composition as de?ned by claim 1, said com 
position comprising a nasal ointmentl 
3. The composition as de?ned in claim ll, said compo 
sition comprising a nasal gel. 
4. The composition as de?ned by claim 2 or 3, 
wherein (i) is a systemically therapeutically effective 
unit B-adrenergic block amount of compound having 
the formula 
5. The composition as de?ned by claim 2 or 3, 
wherein (i) is a systemically therapeutically effective 
unit ,B-adrenergic blocking amount of a nontoxic phar 
maceutically acceptable salt of a compound having the 
formula 
OH 
CHZCHCHIZNHCH(CH3)2. 
6. The composition as de?ned by claim 5, wherein (i) 
is a systemically therapeutically effective unit B-adren 
ergic blocking amount of propranolol hydrochloride or 
propranolol stearate. 
7. A pharmaceutically acceptable nasal composition, 
in dosage unit form, for nasal administration to obtain a 
systemic therapeutic ,B-adrcnergic blocking response in 
a warm-blooded animal, consisting essentially of, per 
nasal dosage unit, (i) a systemically therapeutically ef 
fective unit B-adrenergic blocking amount of proprano 
lol stearate, and (ii) a nontoxic pharmaceutically accept 
able nasal carrier therefor. 
8. The composition as de?ned by claim 7, said com 
position comprising a nasal solution, a nasal suspension 
a nasal ointment, a nasal gel, nasal drops or a nasal 
spray. 
9. The composition as de?ned by claim 7, said com 
position comprising a nasal gel. 
10. The composition as de?ned by claim 9, said com 
position comprising a sustained release nasal gel. 
111. Propranolol stearate. 
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